829 / 1835
PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin
Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and
Biomarker Assessment
Philippe Armand, et al Blood 2015 126:584
•
Conclusions:
PD-1 blockade with pembrolizumab was associated with a
favorable safety profile and a high response rate in a very heavily
pretreated cohort of patients with cHL.
•
Responses appear durable with ongoing follow-up.
•
Biomarker analyses confirm the frequent presence of PD-L1 and PD-L2 in
tumors and further suggest that pembrolizumab results in an expansion of
circulating T- and NK-cell populations, as well as in activation of IFN-γ.